CVS Health, AMD, Yum Brands Rise Premarket; Estée Lauder and Airbnb fall By

© Reuters

By Peter Nurse — Featured Stocks in premarket exchange on Wednesday, November 2. Please refresh for updates.

  • SVC Health (NYSE:) The stock rose 0.9% after the healthcare company raised its full-year profit forecast after beating quarterly estimates on the strong performance of its health insurance and claims management businesses. pharmaceutical benefits.

  • Airbnb (NASDAQ:) Shares fell 6% after the vacation rental company forecast vacation quarter revenue to fall below market expectations, saying a strong dollar had begun to put pressure on its business and that reservations would moderate.

  • Advanced micro-systems (NASDAQ:) The stock rose 6.2% after semiconductors forecast strength in its data center business and vowed to watch spending.

  • Prudential Financial (NYSE:) The stock fell 2% after the insurer posted a decline in quarterly adjusted profit as its assets under management came under pressure from a recent selloff in global markets.

  • Estee Lauder (NYSE:) The stock fell 11% after the cosmetics giant slashed its full-year guidance, citing store closures due to ongoing COVID-19-related shutdowns in key China market.

  • Yum! Brands (NYSE:) Shares rose 0.7% after the fast-food company beat comparable quarterly sales estimates, benefiting from price increases and steady demand.

  • humane (NYSE:) The stock fell 0.3% after the health insurer confirmed its adjusted full-year profit forecast after its , suffering in comparison after its main rivals raised their full-year profit outlook last month .

  • World Paramount (NASDAQ:) The stock fell 8.7% after the media giant missed its result as it struggled with a lack of major content releases and prolonged weakness in ad sales.
  • Canada Goose (NYSE:) Shares fell 9.7% after the clothing retailer cut its full-year revenue and profit forecast, citing COVID-19 restrictions affecting sales in China.

  • GlaxoSmithKline (NYSE:) ADRs rose 1.7% after raising its full-year earnings and sales outlook after better-than-expected results helped by record demand for its shingles vaccine Shingrix.

Comments are closed.